CW February 2010
Volume 19Issue Number 2 February 2010 ISSN 1059380 Everolimus May Offer New Treatment Strategy for Relapsed or Refractory Waldenstrom?s MacroglobulinemiaEverolimus (Afinitor, RAD001) appears to be a safe and effective treatment for patients with Waldenström?s macroglobulinemia who have relapsed or become resistant to prior treatment.
Sources and Additional Reading: Irene Ghobrial, of Dana-Farber Cancer Institute Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW February 2010Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
